Olsen Jørgen, Li Chunze, Skonberg Christian, Bjørnsdottir Inga, Sidenius Ulrik, Benet Leslie Z, Hansen Steen Honoré
Department of Pharmaceutics and Analytical Chemistry, the Danish University of Pharmaceutical Sciences, Copenhagen, Denmark.
Drug Metab Dispos. 2007 May;35(5):758-64. doi: 10.1124/dmd.106.013334. Epub 2007 Feb 15.
Carboxylic acids may be metabolized to acyl glucuronides and acyl-coenzyme A thioesters (acyl-CoAs), which are reactive metabolites capable of reacting with proteins in vivo. In this study, the metabolic activation of tolmetin (Tol) to reactive metabolites and the subsequent formation of Tol-protein adducts in the liver were studied in rats. Two hours after dose administration (100 mg/kg i.p.), tolmetin acyl-CoA (Tol-CoA) was identified by liquid chromatography-tandem mass spectrometry in liver homogenates. Similarly, the acyl-CoA-dependent metabolites tolmetin-taurine conjugate (Tol-Tau) and tolmetin-acyl carnitine ester (Tol-Car) were identified in rat livers. In a rat bile study (100 mg/kg i.p.), the S-acyl glutathione thioester conjugate was identified, providing further evidence of the formation of reactive metabolites such as Tol-CoA or Tol-acyl glucuronide (Tol-O-G), capable of acylating nucleophilic functional groups. Three rats were treated with clofibric acid (150 mg/kg/day i.p. for 7 days) before dose administration of Tol. This resulted in an increase in covalent binding to liver proteins from 0.9 nmol/g liver in control rats to 4.2 nmol/g liver in clofibric acid-treated rats. Similarly, levels of Tol-CoA increased from 0.6 nmol/g to 4.4 nmol/g liver after pretreatment with clofibric acid, whereas the formation of Tol-O-G and Tol-Tau was unaffected by clofibric acid treatment. However, Tol-Car levels increased from 0.08 to 0.64 nmol/g after clofibric acid treatment. Collectively, these results confirm that Tol-CoA is formed in vivo in the rat and that this metabolite can have important consequences in terms of covalent binding to liver proteins.
羧酸可代谢为酰基葡糖醛酸和酰基辅酶A硫酯(酰基-CoA),它们是能够在体内与蛋白质发生反应的活性代谢物。在本研究中,在大鼠体内研究了托美汀(Tol)代谢活化生成活性代谢物以及随后在肝脏中形成托美汀-蛋白质加合物的情况。给药(腹腔注射100mg/kg)两小时后,通过液相色谱-串联质谱法在肝脏匀浆中鉴定出了托美汀酰基辅酶A(Tol-CoA)。同样,在大鼠肝脏中鉴定出了酰基辅酶A依赖性代谢物托美汀-牛磺酸共轭物(Tol-Tau)和托美汀-酰基肉碱酯(Tol-Car)。在一项大鼠胆汁研究(腹腔注射100mg/kg)中,鉴定出了S-酰基谷胱甘肽硫酯共轭物,这进一步证明了能够酰化亲核官能团的活性代谢物如Tol-CoA或托美汀酰基葡糖醛酸(Tol-O-G)的形成。在给予Tol之前,对三只大鼠腹腔注射氯贝酸(150mg/kg/天,持续7天)。这导致与肝脏蛋白质的共价结合从对照大鼠的0.9nmol/g肝脏增加到氯贝酸处理大鼠的4.2nmol/g肝脏。同样,用氯贝酸预处理后,肝脏中Tol-CoA水平从0.6nmol/g增加到4.4nmol/g,而Tol-O-G和Tol-Tau的形成不受氯贝酸处理的影响。然而,氯贝酸处理后Tol-Car水平从0.08增加到0.64nmol/g。总体而言,这些结果证实Tol-CoA在大鼠体内形成,并且这种代谢物在与肝脏蛋白质的共价结合方面可能具有重要影响。